Long non‑coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma
- Danni Deng
- Yi Mo
- Lian Xue
- Naiyuan Shao
- Jie Cao
Affiliations: Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China, Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China
- Published online on: March 16, 2021 https://doi.org/10.3892/etm.2021.9922
Copyright: © Deng
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Gliomas account for 50% of primary brain tumours in the central nervous system. Small ubiquitin‑like modifier 1 pseudogene 3 (SUMO1P3), a newly identified long non‑coding RNA (lncRNA), serves an oncogenic role in various types of cancer. The aim of the present study was to investigate the effect of SUMO1P3 on glioma progression. The results demonstrated that SUMO1P3 expression was upregulated in glioma tissues and cell lines. Furthermore, SUMO1P3 was associated with a poor overall survival of patients with glioma. The results of the in vitro cell proliferation and flow cytometry assays demonstrated that SUMO1P3‑knockdown suppressed cell proliferation and cell cycle. The results of the wound healing and Transwell assays demonstrated that SUMO1P3‑knockdown significantly repressed cell migration and invasion. In addition, SUMO1P3 promoted glioma by regulating the expression levels of β‑catenin, cyclin‑D1, N‑cadherin and E‑cadherin. Overall, the results of the present study suggested that SUMO1P3 may act as an oncogene by regulating cell proliferation, cell cycle, cell migration and invasion in glioma, and may represent a novel diagnostic biomarker and therapeutic target for glioma.